SARS-CoV-2's resistance to remdesivir in vitro With over 108 million reported infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, and nearly 2.4 million deaths, the ongoing pandemic has jeopardized the physical, financial and emotional wellbeing of the global population over the past year. A new preprint research paper posted to the bioRxiv* server discusses the emergence of mutations in the SARS-CoV-2 virus, allowing it to escape the effects of the most commonly used antiviral drug, remdesivir. In an effort to arrest the spread of SARS-CoV-2 infection, drug development and repurposing research has been proceeding at a rapid pace in multiple centers.